

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Antengene Corporation Limited

德琪醫藥有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 6996)

VOLUNTARY ANNOUNCEMENT

THE GROUP'S DOMESTIC OPERATING ENTITY RECEIVED GOVERNMENT GRANT IN THE PRC

This announcement is made by Antengene Corporation Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform the shareholders and potential investors of the Company about the latest development of the Group.

The Company is pleased to announce that on November 27, 2020, Antengene Corporation Co., Ltd. (德琪(浙江)醫藥科技有限公司) (“**Antengene Zhejiang**”), a subsidiary and principal operating entity of the Company in the People’s Republic of China (the “**PRC**”), has received a government grant (the “**Grant**”) of RMB26,780,952.48 from the Administrative Committee (the “**Committee**”) of the Binhai New Area, Shaoxing, Zhejiang Province in the PRC. The Grant was granted by the Committee in recognition of the Company’s contribution in biopharmaceutical innovation in the Binhai New Area. As of the date of this announcement, all the grant has been allocated to the Company’s capital account.

According to the relevant accounting standards, the Company will recognize the Grant as “other income” for the year ending December 31, 2020. The Grant mentioned in this announcement will have certain positive impacts on the annual results of the Company for the year ending December 31, 2020. The specific accounting treatment of the Grant shall be subject to the result of the annual audit by the Company’s independent auditors.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Antengene Corporation Limited
Dr. Jay Mei
Chairman

Hong Kong, November 30, 2020

As at the date of this announcement, the board of directors of the Company comprises Dr. Jay Mei, Mr. John F. Chin and Mr. Yiteng Liu as executive directors; Mr. Xubo Hu, Mr. Zhen Li and Mr. Yanling Cao as non-executive directors; and Mr. Mark J. Alles, Ms. Jing Qian and Mr. Sheng Tang as independent non-executive directors.